Evidence map›Paper›PMID 29167918›Full record

Observational studyEuropean journal of clinical pharmacology2018

Risk factors for QTc interval prolongation.

Charlotte P M Heemskerk, Marieke Pereboom, Karlijn van Stralen, Florine A Berger, Patricia M L A van den Bemt, Aaf F M Kuijper, Ruud T M van der Hoeven, Aukje K Mantel-Teeuwisse, Matthijs L Becker

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Determinants of severe QTFrontiers in psychiatry · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation.International journal of molecular sciences · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Charlotte P M HeemskerkPharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands.
Marieke PereboomPharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands.
Karlijn van StralenSpaarne Gasthuis, Spaarnepoort 1, Hoofddorp, the Netherlands.
Florine A BergerDepartment of Hospital Pharmacy, Erasmus University Medical Centre, s-Gravendijkwal 230, Rotterdam, the Netherlands.
Patricia M L A van den BemtDepartment of Hospital Pharmacy, Erasmus University Medical Centre, s-Gravendijkwal 230, Rotterdam, the Netherlands.
Aaf F M KuijperSpaarne Gasthuis, Spaarnepoort 1, Hoofddorp, the Netherlands.
Ruud T M van der HoevenPharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands.
Aukje K Mantel-TeeuwisseDivision of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Universiteitsweg 99, Utrecht, The Netherlands.
Matthijs L BeckerPharmacy Foundation of Haarlem Hospitals, Boerhaavelaan 24, 2035 RC, Haarlem, The Netherlands. mbecker@sahz.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProlongation of the QTc interval may result in Torsade de Pointes, a ventricular arrhythmia. Numerous risk factors for QTc interval prolongation have been described, including the use of certain drugs. In clinical practice, there is much debate about the management of the risks involved. In this study, we quantified the effect of these risk factors on the length of the QTc interval.

methodsWe analyzed all ECGs that were taken during routine practice between January 2013 and October 2016 in the Spaarne Gasthuis, a general teaching hospital in the Netherlands. We collected laboratory values in the week before the ECG recording and the drugs prescribed. For the identification of risk factors, we used multilevel linear regression analysis to correct for multiple ECG recordings per patient.

resultsWe included 133,359 ECGs in our study, taken in 40,037 patients. Patients using one QT-prolonging drug had a 11.08 ms (95% CI 10.63-11.52; p < 0.001) longer QTc interval. Patients using two QT-prolonging drugs had a 3.04 ms (95% CI 2.06-4.02; p < 0.001) increase in the QTc interval compared to patients using one QT-prolonging drug. Women had a longer QTc interval compared to men (16.30 ms 95% CI 14.59-18.01; p < 0.001). The QTc interval increased with increasing age, but the difference between men and women diminished. Other independent risk factors that significantly prolonged the QTc interval with at least 10 ms were hypokalemia, hypocalcemia, and the use of loop diuretics.

conclusionWe identified and quantified various risk factors for QTc interval prolongation.

Indexed as

AdultAgedDrug-Related Side Effects and Adverse ReactionsElectrocardiographyFemaleHumansLong QT SyndromeMaleMiddle AgedNetherlandsRisk FactorsSex FactorsTime FactorsYoung AdultDrug-related side effects and adverse reactionsElectrocardiographyHospital information systemsLong QT syndrome/chemically inducedRisk assessment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.